Filing Analysis
908 Devices Inc. announced its preliminary financial results for the second quarter and fiscal year ended December 31, 2026. The filing serves as a formal notice that earnings data will be released via press release.
📋 Key Facts
- Company announced preliminary financial results for Q2 and FY 2026 on August 11, 2026.
- The announcement is being made pursuant to Item 2.02 of Form 8-K.
- Detailed results are contained in Exhibit 99.1 (Press Release).
908 Devices Inc. issued 3,213,583 shares of common stock to satisfy earnout obligations related to a prior acquisition of RedWave Technology.
🚩 Red Flags
- Dilution: The issuance of over 3.2 million shares represents a non-cash expense that dilutes existing shareholders.
📋 Key Facts
- Issued 3,213,583 shares of Common Stock on July 8, 2026.
- The issuance was in satisfaction of 'Earnout Consideration' from an Equity Purchase Agreement dated April 29, 2024.
- The earnout was triggered because revenue from RedWave products/services between May 1, 2024, and April 30, 2026, exceeded the $37 million threshold.
- The total potential earnout obligation was up to 4,000,000 shares; the company fulfilled the full amount of the earned portion.
908 Devices Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. The stockholders elected three Class III directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation and its annual voting frequency.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with a quorum representing 76.52% of outstanding shares (28,653,832 shares).
- Elected Class III Directors: Keith L. Crandell, Christopher Brown, Ph.D., and E. Kevin Hrusovsky.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Stockholders approved the compensation of named executive officers.
- Stockholders voted for a one-year frequency for future advisory votes on executive compensation.
908 Devices Inc. acquired Swiss-based NIRLAB SA for a headline price of $15 million, consisting of $13 million in cash and 293,368 shares of common stock. The deal includes a potential $8 million revenue-based earn-out through 2027 and coincided with the company's Q1 2026 financial results announcement.
📋 Key Facts
- Acquisition of NIRLAB SA and its subsidiary NIRLAB Forensics Sàrl completed on May 4, 2026.
- Upfront consideration of $15,000,000 comprised of $13,000,000 in cash and 293,368 shares of common stock.
- Potential earn-out consideration of up to $8,000,000 in shares based on revenue milestones through December 31, 2027.
- Stock consideration was subject to a contractual floor price of $5.88 per share.
- A general holdback of $1.3 million cash and 10% of stock consideration is in place for 12 months to secure indemnity obligations.
- Sellers are subject to a 180-day lock-up period and a 3-year non-compete agreement.
908 Devices Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company also released an updated investor presentation on its corporate website.
📋 Key Facts
- Financial results for Q4 and FY 2025 were reported on March 3, 2026
- Press release furnished as Exhibit 99.1
- Updated investor presentation posted to the 'Events & Presentations' section of the company website
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
908 Devices Inc. has announced its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing serves as a formal notice that earnings data will be released via an accompanying press release.
📋 Key Facts
- Preliminary financial results announced for Q4 and FY 2025 on January 20, 2026.
- The reporting period ended December 31, 2025.
- Results are being furnished as an exhibit (99.1) rather than filed under Section 18 liabilities.
908 Devices Inc. has filed an 8-K to announce its financial results for the third quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing is an announcement of results via press release (Exhibit 99.1)
- Company is classified as an emerging growth company
908 Devices Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 5, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing includes the announcement of financial results via a press release (Exhibit 99.1).
908 Devices Inc. announced the resignation of Jeff George from the Board of Directors and Compensation Committee, effective July 31, 2025. The company simultaneously appointed Dr. Brandi C. Vann to the Board and named Tony J. Hunt as Chair of the Compensation Committee.
🚩 Red Flags
- Board turnover following a significant asset divestiture (bioprocessing product portfolio).
📋 Key Facts
- Jeff George resigned from the Board and Compensation Committee on July 31, 2025; resignation was not due to any disagreement with the Company.
- Dr. Brandi C. Vann appointed to the Board effective August 1, 2025, as a Class I director.
- Tony J. Hunt appointed as Chair of the Compensation Committee on August 1, 2025.
- Dr. Vann's compensation includes $40,000 annual cash and an initial $200,000 equity award (split between RSUs and NQSOs).
- The resignation follows the Company’s recent sale of its bioprocessing product portfolio.
908 Devices Inc. announced the resignation of Marcia Eisenberg from its Board and Compensation Committee, effective June 12, 2025. To fill the vacancy, the company appointed co-founder Dr. Christopher D. Brown to the Board, who is currently under a consulting agreement following the sale of the company's bioprocessing portfolio.
🚩 Red Flags
- Board turnover following a significant asset sale (bioprocessing product portfolio).
- The new director (Dr. Brown) is an employee of the company that purchased a major portion of the firm's assets (Repligen, Inc.).
📋 Key Facts
- Marcia Eisenberg resigned from the Board and Compensation Committee on June 12, 2025; resignation was not due to any disagreement with the Company.
- Dr. Christopher D. Brown appointed to the Board on June 13, 2025, to fill Ms. Eisenberg's vacancy.
- Dr. Brown is a co-founder and former CTO/CPO of the company; he currently serves as VP of R&D, Analytics at Repligen, Inc., which recently purchased the Company’s bioprocessing product portfolio.
- Dr. Brown is currently under a consulting agreement with the Company (dated March 17, 2025) and has waived his right to receive compensation for his initial service as a non-employee director.
- Fenel M. Eloi appointed to the Compensation Committee on June 13, 2025.
908 Devices Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. The meeting resulted in the successful election of Class II Directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 12, 2025.
- Quorum reached with 25,290,637 shares present/represented (70.8% of outstanding shares).
- Class II Directors Kevin J. Knopp, Tony J. Hunt, and Mark Spoto were elected.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
908 Devices Inc. announced its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2025
- Announcement date: May 13, 2025
- The company is classified as an 'emerging growth company' under SEC rules.
908 Devices Inc. filed an amendment to its previous 8-K to include required pro forma financial information following the completed sale of its bioprocessing desktop devices business portfolio.
🚩 Red Flags
- Divestiture of a business unit (desktop devices) may indicate a strategic pivot or a need to raise cash, though context on the sale price is not in this specific text.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to a report originally filed on March 4, 2025.
- The company has consummated the sale of its 'Business' consisting of a portfolio of desktop devices used in bioprocessing process analytical technologies.
- The amendment provides unaudited pro forma condensed consolidated financial information as required by Item 9.01(b).
- The filing includes Exhibit 99.1 containing the pro forma financial data.
908 Devices Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. The filing serves as a formal notice of the earnings release.
📋 Key Facts
- Reported date: March 4, 2025
- Period covered: Fourth quarter and fiscal year ended December 31, 2024
- Company status: Emerging growth company
- Exchange: NASDAQ Global Market (Ticker: MASS)
908 Devices Inc. has completed the sale of its entire desktop device business (including 908 Devices GmbH) to Repligen Corporation and Repligen GmbH for $70 million. This transaction represents a significant strategic pivot, as the company is divesting its core bioprocessing process analytical technology portfolio.
🚩 Red Flags
- Significant divestiture of 'the entirety' of the Company’s portfolio of desktop devices, suggesting a major shift in corporate identity or potential liquidity needs.
- Non-compete restriction for 5 years significantly limits future growth opportunities in this sector.
📋 Key Facts
- Sale price: $70,000,000 (subject to working capital adjustments).
- Assets sold include all issued and outstanding equity of 908 Devices GmbH and certain liabilities/assets related to the desktop device business.
- Purchasers: Repligen Corporation (US) and Repligen GmbH (Germany).
- Non-compete clause: Company is barred from competing in this business for 5 years; non-solicitation of employees for 18 months.
- Transition Services Agreement (TSA): Company will provide tech, financial, and operational services through December 31, 2025.
- Ongoing revenue streams: The company will supply products to Purchasers under a new supply agreement and license IP used in the business.
908 Devices Inc. announced a significant organizational restructuring involving an 11% workforce reduction and the relocation of all manufacturing operations from Boston, MA to North Carolina and Connecticut. These moves are aimed at reducing annual cash burn and generating approximately $6.6 million in combined annual cost savings starting in 2025/2026.
🚩 Red Flags
- Workforce reduction (11%) indicates a need to reduce cash burn, suggesting liquidity or profitability pressures.
- Management cites a 'slower growth market environment' as a reason for restructuring.
- Relocation of all manufacturing operations suggests a significant shift in operational footprint and potential transition risks.
📋 Key Facts
- Implementing an ~11% workforce reduction to reduce annual cash burn due to a 'slower growth market environment'.
- Relocating all manufacturing from Boston, MA to Morrisville, NC and Danbury, CT by end of Q3 2025.
- Workforce reduction expected to save ~$4.2 million annually starting in 2025.
- Manufacturing relocation expected to save ~$2.4 million annually starting in 2026.
- One-time severance charge for workforce reduction estimated between $0.4 million and $0.6 million.
- Relocation costs are not yet fully estimated but are not anticipated to be material.
908 Devices Inc. filed an 8-K to announce the posting of an updated Investor Presentation on its website for use in meetings with investors and analysts.
📋 Key Facts
- Company posted an updated Investor Presentation on ir.908devices.com on August 30, 2024.
- The presentation is intended for use by management in meetings with investors, analysts, and other interested parties.
- Information disclosed via the website may be considered material.
908 Devices Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing is a standard earnings release under Item 2.02
- Company is an emerging growth company
908 Devices Inc. filed an amendment to its previous 8-K to provide required historical financial statements and pro forma information following the acquisition of CAM2 Technologies, LLC (d/b/a RedWave Technology) on April 29, 2024.
🚩 Red Flags
- None identified in this amendment; filing is a procedural requirement for previously disclosed acquisition.
📋 Key Facts
- Acquisition of all issued and outstanding equity interests of CAM2 Technologies, LLC (RedWave Technology) closed on April 29, 2024.
- RedWave Technology has become a wholly-owned subsidiary of 908 Devices Inc.
- The filing includes audited financial statements for RedWave as of December 31, 2023, and unaudited condensed financial statements as of March 31, 2024.
- Pro forma financial information was provided to show the impact of the combination on the company's balance sheet and income statement.
908 Devices Inc. announced the appointment of Michele M. Leonhart to its Board of Directors, expanding the board from eight to nine members.
📋 Key Facts
- Appointment date: June 25, 2024
- Director Class: Class I director
- Term expiration: Annual meeting in June 2027
- Annual cash compensation: $40,000 paid quarterly
- Initial equity award value: $200,000 (50% RSUs / 50% NQSOs)
- RSU vesting schedule: Annual over three years
- NQSO vesting schedule: Monthly over three years
- Annual equity award value for continuing directors: $135,000 (50% RSUs / 50% NQSOs)
908 Devices Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the election of Class I Directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Quorum reached with 29,482,308 shares present/represented (89.4% of outstanding shares).
- Fenel M. Eloi and Jeffrey P. George were elected to the Board as Class I Directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
908 Devices Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that earnings information is being furnished via a press release.
📋 Key Facts
- Report date: April 30, 2024
- Reporting period: First Quarter ended March 31, 2024
- Company status: Emerging growth company
- Exchange: NASDAQ Global Market (Ticker: MASS)
908 Devices Inc. has completed the acquisition of RedWave Technology, a provider of portable FTIR spectroscopic analyzers, for $45 million in cash and approximately 1.5 million shares of common stock.
🚩 Red Flags
- Potential dilution from up to 4,000,000 earnout shares if revenue targets are met.
- Significant cash outlay ($45M) relative to micro-cap scale (implied by context).
📋 Key Facts
- Acquisition closed on April 29, 2024.
- Total Cash Consideration: $45.0 million (subject to working capital/debt adjustments).
- Equity Consideration: 1,497,171 unregistered shares of common stock issued at closing.
- Earnout Provision: Up to 4,000,000 additional shares contingent on RedWave generating $37M–$45M in revenue between May 2024 and April 2026.
- Indemnification Escrow: $4.5 million of the cash consideration held for 12 months.
- Lock-Up Agreement: Beneficial sellers are subject to a 180-day lock-up period on closing shares.
908 Devices Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The filing is a standard earnings release notification under Item 2.02.
📋 Key Facts
- Report date: March 5, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- Company status: Emerging growth company
- Exchange: NASDAQ Global Market (Ticker: MASS)